請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/83843完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林思洸(Sze-Kwan Lin) | |
| dc.contributor.author | Ying-Chiang Liu | en |
| dc.contributor.author | 劉盈江 | zh_TW |
| dc.date.accessioned | 2023-03-19T21:20:17Z | - |
| dc.date.copyright | 2022-10-03 | |
| dc.date.issued | 2022 | |
| dc.date.submitted | 2022-07-25 | |
| dc.identifier.citation | 1. Kakehashi, S., H.R. Stanley, and R.J. Fitzgerald, The Effects of Surgical Exposures of Dental Pulps in Germ-Free and Conventional Laboratory Rats. Oral Surg Oral Med Oral Pathol, 1965. 20: p. 340-9. 2. Wang, C.Y., N. Tani-Ishii, and P. Stashenko, Bone-resorptive cytokine gene expression in periapical lesions in the rat. Oral Microbiol Immunol, 1997. 12(2): p. 65-71. 3. Bezerra, M.C., et al., RANK, RANKL and osteoprotegerin in arthritic bone loss. Braz J Med Biol Res, 2005. 38(2): p. 161-70. 4. Sundqvist, G., Associations between microbial species in dental root canal infections. Oral Microbiol Immunol, 1992. 7(5): p. 257-62. 5. Sj?gren, U., et al., Factors affecting the long-term results of endodontic treatment. Journal of Endodontics, 1990. 16(10): p. 498-504. 6. Friedman, S., S. Abitbol, and H.P. Lawrence, Treatment outcome in endodontics: the Toronto Study. Phase 1: initial treatment. Journal of endodontics, 2003. 29(12): p. 787-793. 7. Farzaneh, M., S. Abitbol, and S. Friedman, Treatment outcome in endodontics: the Toronto study. Phases I and II: Orthograde retreatment. Journal of Endodontics, 2004. 30(9): p. 627-633. 8. Law, A.S., et al., Localization and changes in NADPH-diaphorase reactivity and nitric oxide synthase immunoreactivity in rat pulp following tooth preparation. J Dent Res, 1999. 78(10): p. 1585-95. 9. MacMicking, J., Q.W. Xie, and C. Nathan, Nitric oxide and macrophage function. Annu Rev Immunol, 1997. 15: p. 323-50. 10. Charles, I.G., et al., Cloning, characterization, and expression of a cDNA encoding an inducible nitric oxide synthase from the human chondrocyte. Proceedings of the National Academy of Sciences, 1993. 90(23): p. 11419-11423. 11. Geller, D.A., et al., Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proceedings of the National Academy of Sciences, 1993. 90(8): p. 3491-3495. 12. Sethi, S. and M. Dikshit, Modulation of polymorphonuclear leukocytes function by nitric oxide. Thrombosis research, 2000. 100(3): p. 223-247. 13. Beckman, J.S. and W.H. Koppenol, Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol, 1996. 271(5 Pt 1): p. C1424-37. 14. Lappin, D.F., et al., Inducible nitric oxide synthase expression in periodontitis. J Periodontal Res, 2000. 35(6): p. 369-73. 15. Takeichi, O., et al., Cytokine regulation on the synthesis of nitric oxide in vivo by chronically infected human polymorphonuclear leucocytes. Immunology, 1998. 93(2): p. 275-80. 16. Hama, S., et al., Involvement of inducible nitric oxide synthase and receptor for advanced glycation end products in periapical granulomas. J Endod, 2007. 33(2): p. 137-41. 17. Valera, M.C., et al., Towards optimization of estrogen receptor modulation in medicine. Pharmacol Ther, 2018. 189: p. 123-129. 18. Bopassa, J.C., et al., A novel estrogen receptor GPER inhibits mitochondria permeability transition pore opening and protects the heart against ischemia-reperfusion injury. American Journal of Physiology-Heart and Circulatory Physiology, 2010. 298(1): p. H16-H23. 19. Cooke, P.S., et al., Estrogens in male physiology. Physiological reviews, 2017. 97(3): p. 995-1043. 20. Love, R.R., et al., Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. New England journal of medicine, 1992. 326(13): p. 852-856. 21. Schweikart, K.M., et al., Comparative uterotrophic effects of endoxifen and tamoxifen in ovariectomized Sprague-Dawley rats. Toxicologic pathology, 2014. 42(8): p. 1188-1196. 22. Shen, T.Y., C. Strong, and T. Yu, Age at menopause and mortality in Taiwan: A cohort analysis. Maturitas, 2020. 136: p. 42-48. 23. Ejiri, S., et al., Estrogen deficiency and its effect on the jaw bones. J Bone Miner Metab, 2008. 26(5): p. 409-15. 24. Tanaka, M., et al., Effects of ovariectomy on trabecular structures of rat alveolar bone. J Periodontal Res, 2002. 37(2): p. 161-5. 25. Binte Anwar, R., et al., Relationship between porotic changes in alveolar bone and spinal osteoporosis. J Dent Res, 2007. 86(1): p. 52-7. 26. Hsieh, Y., H. Devlin, and F. McCord, The effect of ovariectomy on the healing tooth socket of the rat. Archives of oral biology, 1995. 40(6): p. 529-531. 27. Shimizu, M., et al., Bone wound healing after maxillary molar extraction in ovariectomized aged rats: quantitative backscattered electron image analysis. The Anatomical Record: An Official Publication of the American Association of Anatomists, 2000. 259(1): p. 76-85. 28. Martin-Millan, M., et al., The estrogen receptor-α in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Molecular endocrinology, 2010. 24(2): p. 323-334. 29. Emmanuelle, N.E., et al., Critical Role of Estrogens on Bone Homeostasis in Both Male and Female: From Physiology to Medical Implications. Int J Mol Sci, 2021. 22(4). 30. Howard, B.V., G. Ruotolo, and D.C. Robbins, Obesity and dyslipidemia. Endocrinology and Metabolism Clinics of North America, 2003. 32(4): p. 855-867. 31. McDonnell, D.P., et al., Obesity, cholesterol metabolism, and breast cancer pathogenesis. Cancer Res, 2014. 74(18): p. 4976-82. 32. Howe, V., et al., Cholesterol homeostasis: How do cells sense sterol excess? Chem Phys Lipids, 2016. 199: p. 170-178. 33. Umetani, M., et al., The cholesterol metabolite 27-hydroxycholesterol promotes atherosclerosis via proinflammatory processes mediated by estrogen receptor alpha. Cell Metab, 2014. 20(1): p. 172-82. 34. Keren, Z. and T.C. Falik-Zaccai, Cerebrotendinous xanthomatosis (CTX): a treatable lipid storage disease. Pediatric Endocrinology Reviews: PER, 2009. 7(1): p. 6-11. 35. Lupattelli, G., et al., Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women. Metabolism, 2004. 53(6): p. 744-8. 36. DuSell, C.D., et al., The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. Endocrinology, 2010. 151(8): p. 3675-85. 37. Nelson, E.R., et al., The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver X receptors. Endocrinology, 2011. 152(12): p. 4691-705. 38. Cuzick, J., et al., Preventive therapy for breast cancer: a consensus statement. The Lancet Oncology, 2011. 12(5): p. 496-503. 39. Kanis, J.A., et al., European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int, 2019. 30(1): p. 3-44. 40. B?rzsei, D., et al., Distinct approaches of raloxifene: its far-reaching beneficial effects implicating the HO-system. Biomolecules, 2020. 10(3): p. 375. 41. Luvizuto, E.R., et al., Osteocalcin immunolabeling during the alveolar healing process in ovariectomized rats treated with estrogen or raloxifene. Bone, 2010. 46(4): p. 1021-9. 42. Ramalho-Ferreira, G., et al., Alveolar bone dynamics in osteoporotic rats treated with raloxifene or alendronate: confocal microscopy analysis. J Biomed Opt, 2015. 20(3): p. 038003. 43. Ramalho-Ferreira, G., et al., Raloxifene enhances peri-implant bone healing in osteoporotic rats. Int J Oral Maxillofac Surg, 2015. 44(6): p. 798-805. 44. Park, S., et al., Effect of Raloxifene on Bone Formation Around Implants in the Osteoporotic Rat Maxilla: Histomorphometric and Microcomputed Tomographic Analysis. Int J Oral Maxillofac Implants, 2020. 35(2): p. 249-456. 45. Gomes-Filho, J.E., et al., Raloxifene modulates regulators of osteoclastogenesis and angiogenesis in an oestrogen deficiency periapical lesion model. Int Endod J, 2015. 48(11): p. 1059-68. 46. Gomes-Filho, J.E., et al., Effect of raloxifene on periapical lesions in ovariectomized rats. J Endod, 2015. 41(5): p. 671-5. 47. Harik-Khan, R. and R.P. Holmes, Estimation of 26-hydroxycholesterol in serum by high-performance liquid chromatography and its measurement in patients with atherosclerosis. Journal of steroid biochemistry, 1990. 36(4): p. 351-355. 48. Hirayama, T., et al., Serum concentration of 27-hydroxycholesterol predicts the effects of high-cholesterol diet on plasma LDL cholesterol level. Hepatol Res, 2009. 39(2): p. 149-56. 49. Pandak, W.M., et al., Transport of cholesterol into mitochondria is rate-limiting for bile acid synthesis via the alternative pathway in primary rat hepatocytes. J Biol Chem, 2002. 277(50): p. 48158-64. 50. Yang, Y.H., et al., Endogenous estrogen regulation of inflammatory arthritis and cytokine expression in male mice, predominantly via estrogen receptor alpha. Arthritis Rheum, 2010. 62(4): p. 1017-25. 51. de Moura, E.D.M., et al., Diet-induced obesity in animal models: points to consider and influence on metabolic markers. Diabetol Metab Syndr, 2021. 13(1): p. 32. 52. Blancas-Velazquez, A., S.E. la Fleur, and J. Mendoza, Effects of a free-choice high-fat high-sugar diet on brain PER2 and BMAL1 protein expression in mice. Appetite, 2017. 117: p. 263-269. 53. Matias, A.M., et al., Differential effects of high sugar, high lard or a combination of both on nutritional, hormonal and cardiovascular metabolic profiles of rodents. Nutrients, 2018. 10(8): p. 1071. 54. Messalli, E.M., et al., Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas, 2007. 56(1): p. 38-44. 55. Cao, Y., et al., Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res, 2002. 17(12): p. 2237-46. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/83843 | - |
| dc.description.abstract | 根尖病變是一種由微生物感染根管系統所誘發的免疫發炎反應,根尖骨吸收為臨床重要表徵。參與根尖病變發展的細胞和發炎介質與引發骨質疏鬆的成員相似,而停經造成的雌激素(17β-estradiol, E2)缺乏、及肥胖合併高膽固醇血症皆是骨質疏鬆的高危險因子。27-羥基膽固醇(27-hydroxycholesterol, 27-HC),一種內生性選擇性雌激素受體調節物(Selective estrogen receptor modulator, SERMs),扮演引渡者串聯起肥胖、停經與骨質疏鬆之病理關聯。Raloxifene作為第二代SERM,廣泛用於治療停經後婦女之骨質疏鬆,然而與根尖組織相關研究尚未明朗。因此本研究目的為驗證膽固醇、E2及27-HC三者於根尖病變發展之關係,及raloxifene臨床應用之潛能。實驗以巨噬細胞株(J774)分別在膽固醇、E2及27-HC刺激下,以ELISA檢測27-HC濃度;西方墨點法分析CYP27A1及iNOS的表現量。25隻6週大雌性Sprague-Dawley大鼠進行根尖病變誘導實驗,分別給予卵巢切除(Ovariectomy, OVX)、高脂飲食(High fat diet, HFD)及raloxifene,實驗分為五組:ND、ND/OVX、HFD、HFD/OVX及HFD/OVX/Ralo(1 mg/kg/d),以傳統根尖片及微米級電腦斷層掃描(micro-CT)監測根尖病變發展;透過ELISA評估病灶中27-HC濃度及血液中膽固醇濃度。研究結果顯示J774中,膽固醇會刺激粒腺體內CYP27A1表現以促進27-HC生成,然而當27-HC至一定濃度時會產生回饋抑制CYP27A1的表現。給予E2和raloxifene皆會抑制27-HC對iNOS的誘導作用。動物實驗方面,血液中膽固醇濃度與體重增加百分比有正相關。在影像分析中,肥胖與停經會加劇根尖病變的病程,而raloxifene可減緩病灶的發展。總結而言,膽固醇會刺激巨噬細胞生成27-HC,進而啟動發炎反應;而停經導致E2的抗發炎作用喪失,因而加劇根尖病變發展。Raloxifene可逆轉E2缺乏的影響,抑制發炎相關介質,減弱根尖病變中的發炎性骨吸收,暗示著raloxifene於臨床應用的潛能。 | zh_TW |
| dc.description.abstract | Apical lesion is an immune inflammatory response originated from microbial infection of the root canal system. Resorption of periapical bone is a clinically cardinal sign. Most cells and inflammatory mediators involved in the pathogenesis of periapical lesions also participate in that of osteoporosis. Estrogen (17β-estradiol, E2) deprivation by menopause, and obesity comorbidity with hypercholesterolemia are both high risk factors for osteoporosis. 27-hydroxycholesterol (27-HC), an endogenous selective estrogen receptor modulator (SERM), links the pathogenesis of obesity, menopause and osteoporosis. Raloxifene, a second generation SERM, is widely used in treatment of osteoporosis in postmenopausal women. However, the research about raloxifene and periapical tissue is still no clear. Therefore, the purpose of this study is to verify the relationship between cholesterol, E2 and 27-HC in the propagation of apical lesions, and the therapeutic potential of raloxifene. Macrophage cell line (J774) is treated with cholesterol, E2 and 27-HC separately. The concentration of 27-HC is detected by ELISA kit. Western blot is used to analyze CYP27A1 and iNOS expression. Twenty-five female Sprague–Dawley rats at 6 weeks of age are subjected to apical lesion induction, and are received OVX, HFD, or raloxifene respectively. The experiment is divided into ?ve groups: ND, ND/OVX, HFD, HFD/OVX, and HFD/OVX/Ralo (1 mg/kg/d). Progression of the apical lesion is monitored by conventional radiography and microcomputed tomography. The concentration of 27-HC in apical lesion and serum cholesterol are assessed by ELISA kit. The results indicate that cholesterol enhances the formation of 27-HC by increasing CYP27A1 expression in J774 mitochondria. Interestingly, 27-HC shows feedback inhibition on CYP27A1 expression when it reaches a certain concentration. Estrogen and raloxifene both attenuate the induction effect of 27-HC on iNOS expression. In animal studies, the level of serum cholesterol has a positive correlation with the percentage of weight gain. Moreover, the image analysis shows that obesity and menopause aggravate the propagation of apical lesions; by contrast, raloxifene alleviates the progression of the disease. In summary, cholesterol stimulates macrophages to produce 27-HC, which in turn initiates an inflammatory response. Besides, loss of the anti-inflammatory effect of estrogen due to menopause exacerbates the development of apical lesions. Raloxifene reverses the effect of estrogen deficiency, inhibits inflammatory mediators, and suppresses the progression of inflammatory bone resorption in periapical lesions. The above results imply that raloxifene gives light on a novel therapeutic strategy in apical periodontitis. | en |
| dc.description.provenance | Made available in DSpace on 2023-03-19T21:20:17Z (GMT). No. of bitstreams: 1 U0001-2207202203461700.pdf: 1977251 bytes, checksum: 29488a435721cade980e9d00405dd0f7 (MD5) Previous issue date: 2022 | en |
| dc.description.tableofcontents | 口試委員會審定書 i 中文摘要 ii 英文摘要 iii 目 錄 v 圖目錄 viii 表目錄 ix 縮寫表 x 第一章 導論 1 1.1 根尖病變與發炎反應之關係 1 1.1.1 根尖病變之病理機制 1 1.1.2 當代根管治療的原則與發展之瓶頸 2 1.1.3 免疫的雙面刃:一氧化氮(NO)與一氧化氮合成?(NOS) 2 1.2 停經(Menopause) 3 1.2.1 雌激素(Estrogen)所扮演的角色 3 1.2.2 選擇性雌激素受體調節物(SERMs) 3 1.2.3 停經對根尖病變之影響 4 1.3 肥胖(Obesity)與高膽固醇血症(Hypercholesterolemia) 5 1.3.1 膽固醇在人體內的代謝與恆定 5 1.3.2 氧固醇(Oxysterol) 6 1.4 內生性的SERM:27-羥基膽固醇(27-hydroxycholesterol, 27-HC) 6 1.4.1 固醇27-烴化?(sterol 27-hydroxylase, CYP27A1) 6 1.4.2 27-HC的重要性 6 1.4.3 27-HC與根尖病變之關聯 7 1.5 Raloxifene 8 1.5.1 SERM藥物:Raloxifene 8 1.5.2 Raloxifene於牙科的應用 8 第二章 實驗目的 9 第三章 材料與方法 10 3.1 實驗細胞株 10 3.2 蛋白質的萃取 10 3.2.1 細胞內蛋白質的萃取 10 3.2.2 細胞內之粒線體/細胞質蛋白質的萃取 10 3.2.3 蛋白質的定量 11 3.3 西方墨點法(Western blot) 12 3.4 酵素免疫分析法(Enzyme-linked immunosorbent assay, ELISA) 13 3.5 誘導根尖病變動物模型(Animal Models of Periapical Lesions) 14 3.5.1 誘導根尖病變之生成 14 3.5.2 Raloxifene的投予 15 3.5.3 檢體製備與組織切片分析 15 第四章 實驗結果 16 4.1 膽固醇對細胞內27-HC表現量的影響 16 4.1.1 膽固醇會刺激細胞內27-HC的合成 16 4.2 膽固醇、27-HC與CYP27A1之關係 16 4.2.1 27-HC會透過負回饋機制抑制CYP27A1 16 4.2.2 膽固醇會促進CYP27A1的表現 16 4.3 E2會抑制27-HC誘導下增加的iNOS表現量 17 4.3.1 27-HC會刺激iNOS的表現 17 4.3.2 E2會抑制27-HC誘導下增加的iNOS表現量 17 4.4 肥胖與停經對根尖病變發展之影響 17 4.4.1 不同條件下,對體重變化的影響 17 4.4.2 不同條件下,對血液中膽固醇濃度的影響 18 4.4.3 肥胖與停經會加劇根尖病變的發展 18 4.4.4 不同條件下,根尖病變中27-HC濃度之分析 18 4.5 Raloxifene會減緩肥胖與停經對根尖病變的影響 18 4.5.1 Raloxifene會抑制27-HC誘導下增加的iNOS表現量 18 4.5.2 Raloxifene可以減緩肥胖與停經加劇根尖病變發展的現象 19 第五章 討論 20 5.1 膽固醇會促進27-HC的生成 20 5.1.1 27-HC的負回饋調控 20 5.2 雌激素會抑制27-HC誘發的發炎反應 21 5.3 肥胖與停經對根尖病變發展之影響 22 5.3.1 高脂飲食與停經對體重變化的影響 22 5.3.2 根尖病變大小與27-HC濃度之關係 23 5.4 Raloxifene可能具有減緩根尖病灶病程發展之效果 24 第六章 結論 25 第七章 未來展望 26 參考文獻 27 附錄 31 | |
| dc.language.iso | zh-TW | |
| dc.subject | Raloxifene | zh_TW |
| dc.subject | 27-羥基膽固醇 | zh_TW |
| dc.subject | 根尖病變 | zh_TW |
| dc.subject | 雌激素 | zh_TW |
| dc.subject | 膽固醇 | zh_TW |
| dc.subject | cholesterol | en |
| dc.subject | 27-hydroxycholesterol | en |
| dc.subject | apical lesion | en |
| dc.subject | raloxifene | en |
| dc.subject | estrogen | en |
| dc.title | 27-羥基膽固醇與肥胖、停經和根尖病變發展之關聯:作用機轉及臨床治療潛能 | zh_TW |
| dc.title | 27-hydroxycholesterol Annulates Obesity, Menopause, and Periapical Lesion Pathogenesis: Mechanisms and Therapeutic Potentials | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 110-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 郭生興(Sang-Heng Kok),洪志遠(Chi-Yuan Hong) | |
| dc.subject.keyword | 27-羥基膽固醇,根尖病變,雌激素,膽固醇,Raloxifene, | zh_TW |
| dc.subject.keyword | 27-hydroxycholesterol,apical lesion,estrogen,cholesterol,raloxifene, | en |
| dc.relation.page | 47 | |
| dc.identifier.doi | 10.6342/NTU202201623 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2022-07-26 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床牙醫學研究所 | zh_TW |
| 顯示於系所單位: | 臨床牙醫學研究所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-2207202203461700.pdf 未授權公開取用 | 1.93 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
